Ovum transport in women treated with methyl ergonovine
Author
dc.contributor.author
Guiloff, E.
Author
dc.contributor.author
Polo, A. A.
Author
dc.contributor.author
Ortiz, M. E.
Author
dc.contributor.author
Salvatierra, A. M.
Author
dc.contributor.author
Guerrero, R.
Author
dc.contributor.author
Croxatto, H. B.
Admission date
dc.date.accessioned
2019-01-29T15:46:07Z
Available date
dc.date.available
2019-01-29T15:46:07Z
Publication date
dc.date.issued
1979
Cita de ítem
dc.identifier.citation
American Journal of Obstetrics and Gynecology, Volumen 134, Issue 3, 2018, Pages 321-324
Identifier
dc.identifier.issn
00029378
Identifier
dc.identifier.other
10.1016/S0002-9378(16)33040-X
Identifier
dc.identifier.uri
https://repositorio.uchile.cl/handle/2250/162337
Abstract
dc.description.abstract
The location of ova in the genital tract was studied between 24 and 120 hours after the luteinizing hormone (LH) surge in 32 women who had been treated with methyl ergonovine in doses known to stimulate tubal contractility. Thirteen eggs were found in the fallopian tubes, between 48 and 120 hours after the LH peak, and no eggs were recovered from the endometrial cavity. No significant difference in tubal ovum recovery or in tubal segmental distribution of ova was found in comparison with these parameters in an untreated control group. These results indicate that stimulation of tubal contractility with methyl ergonovine does not accelerate ovum transport through the fallopian tubes in the human.